Jonathan D. Marotti

Jonathan D. Marotti

Auto-generated profile, based on publicly available information

Jonathan D. Marotti

Department of Pathology, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 July 2015 in Clinical Epigenetics
Verified
Journal Article
Open access
PDF file
KJKevin C. Johnson
Kevin C. Johnson
DKDevin C Koestler
Devin C Koestler
TFThomas Fleischer
Thomas Fleischer
PCPanpan Chen
Panpan Chen
EJErik G. Jenson
Erik G. Jenson
BCBrock C. Christensen
Brock C. Christensen
Ductal carcinoma in situ (DCIS) is a heterogeneous, pre-invasive lesion associated with an increased risk for future invasive ductal carcinoma. However, accurate risk stratification for development of invasive disease and appropriate treatment decisions remain clinical challenges. DNA methylation alterations are early events in the progression of cancer and represent emerging molecular markers that may predict invasive recurrence more accurately than traditional measures of DCIS prognosis. We measured DNA methylation using the Illumina HumanMethylation450K array of estrogen-receptor positive DCIS (n = 40) and adjacent-normal (n = 15) tissues from subjects in the New Hampshire Mammography Network longitudinal breast imaging registry. We identified locus-specific methylation differences between DCIS and matched adjacent-normal tissue (95,609 CpGs, Q < 0.05). Among 40 DCIS cases, 13 later developed invasive disease and we identified 641 CpG sites that exhibited differential DNA methylation (P < 0.01 and median |∆β| > 0.1) in these cases compared with age-matched subjects without invasive disease. The set of differentially methylated CpG loci associated with disease progression was enriched in homeobox-containing genes (P = 1.3E-09) and genes involved with limb morphogenesis (P = 1.0E-05). In an independent cohort, a subset of genes with progression-related differential methylation between DCIS and invasive breast cancer were confirmed. Further, the functional relevance of these genes’ regulation by methylation was demonstrated in early stage breast cancers from The Cancer Genome Atlas database. This work contributes to the understanding of epigenetic alterations that occur in DCIS and illustrates the potential of DNA methylation as markers of DCIS progression.

27 September 2012 in Acta Cytologica
Verified
Journal Article
Closed access
PDF file
JMJonathan D. Marotti
Jonathan D. Marotti
VJVickie Johncox
Vickie Johncox
DNDavid Ng
David Ng
JGJorge L. Gonzalez
Jorge L. Gonzalez
VPVijayalakshmi Padmanabhan
Vijayalakshmi Padmanabhan
Objective: To evaluate the implementation of telecytology in an academic cytology service for immediate assessment of endoscopic ultrasound (EUS) and endobronchoscopic ultrasound (EBUS) fine-needle aspiration (FNA). Study Design: Telecytology was evaluated over a 10-month period. Using an Olympus BX41® microscope and an Olympus DP72® camera with Olympus cellSens® software, real-time dynamic images of air-dried Diff-Quik®-stained smears were transmitted by a cytopathology fellow or cytotechnologist using a secure internet connection. The cytopathologists remotely accessed the real-time images on a computer in their office and rendered immediate assessments. Mean procedure times, and preliminary and final diagnoses were compared between telecytology and conventional on-site evaluation. Results: Two hundred and forty consecutive EUS-FNA and EBUS-FNA procedures with immediate assessments were performed during the evaluation period, of which 158 (66%) utilized telecytology and 82 (34%) did not utilize telecytology. The mean procedure time required for cytotechnologists and cytology fellows was 1.1 h for both conventional on-site and telecytology evaluations. The mean procedure time for cytopathologists was 0.74 h for conventional on-site evaluations and 0.2 h for telecytology. Conclusions: Incorporation of telecytology for immediate assessment of EUS-FNA increased cytopathologist efficiency.

8 January 2025 in Cancer Research
Verified
Journal Article
Closed access
STSteven Tau
Steven Tau
MCMary D. Chamberlin
Mary D. Chamberlin
HYHuijuan Yang
Huijuan Yang
JMJonathan D. Marotti
Jonathan D. Marotti
PMPatricia C. Muskus
Patricia C. Muskus
TMTodd W Miller
Todd W Miller
Despite adjuvant treatment with endocrine therapies, estrogen receptor–positive (ER+) breast cancers recur in a significant proportion of patients. Recurrences are attributable to clinically undetectable endocrine-tolerant persister cancer cells that retain tumor-forming potential. Therefore, strategies targeting such persister cells may prevent recurrent disease. Using CRISPR-Cas9 genome-wide knockout screening in ER+ breast cancer cells, we identified a survival mechanism involving metabolic reprogramming with reliance upon mitochondrial respiration in endocrine-tolerant persister cells. Quantitative proteomic profiling showed reduced levels of glycolytic proteins in persisters. Metabolic tracing of glucose revealed an energy-depleted state in persisters, in which oxidative phosphorylation was required to generate ATP. A phase II clinical trial was conducted to evaluate changes in mitochondrial markers in primary ER+/HER2– breast tumors induced by neoadjuvant endocrine therapy (NCT04568616). In an analysis of tumor specimens from 32 patients, tumors exhibiting residual cell proliferation after aromatase inhibitor–induced estrogen deprivation with letrozole showed increased mitochondrial content. Genetic profiling and barcode lineage tracing showed that endocrine-tolerant persistence occurred stochastically without genetic predisposition. Pharmacologic inhibition of mitochondrial complex I suppressed the tumor-forming potential of persisters in mice and synergized with the antiestrogen drug fulvestrant to induce regression of patient-derived xenografts. These findings indicate that mitochondrial metabolism is essential in endocrine-tolerant persister ER+ breast cancer cells and warrant the development of treatment strategies to leverage this vulnerability for treating breast cancer. Significance: Persister cancer cells that survive endocrine therapy exhibit increased energetic dependence upon mitochondria for survival and tumor regrowth potential, indicating that therapies targeting this metabolic dependency could help prevent disease recurrence.

1 October 2016 in The Breast
Verified
Journal Article
Open access
JDJ.L. Dillon
J.L. Dillon
SMS.M. Mockus
S.M. Mockus
GAG. Ananda
G. Ananda
VSV. Spotlow
V. Spotlow
WWW.A. Wells
W.A. Wells
JMJ.D. Marotti
J.D. Marotti
The expanded gene panel identified a variety of clinically actionable gene alterations in TNBCs. The identification of such variants increases the possibility for new therapeutic interventions and clinical trial eligibility for TNBC patients.

26 July 2023 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
NTNicole A. Traphagen
Nicole A. Traphagen
GSGary N. Schwartz
Gary N. Schwartz
STSteven Tau
Steven Tau
ARAlyssa M. Roberts
Alyssa M. Roberts
AJAmanda Jiang
Amanda Jiang
TMTodd W Miller
Todd W Miller
Purpose: Clinical evidence indicates that treatment with estrogens elicits anticancer effects in ∼30% of patients with advanced endocrine-resistant estrogen receptor α (ER)-positive breast cancer. Despite the proven efficacy of estrogen therapy, its mechanism of action is unclear and this treatment remains underused. Mechanistic understanding may offer strategies to enhance therapeutic efficacy. Experimental Design: We performed genome-wide CRISPR/Cas9 screening and transcriptomic profiling in long-term estrogen-deprived ER+ breast cancer cells to identify pathways required for therapeutic response to the estrogen 17β-estradiol (E2). We validated findings in cell lines, patient-derived xenografts (PDX), and patient samples, and developed a novel combination treatment through testing in cell lines and PDX models. Results: Cells treated with E2 exhibited replication-dependent markers of DNA damage and the DNA damage response prior to apoptosis. Such DNA damage was partially driven by the formation of DNA:RNA hybrids (R-loops). Pharmacologic suppression of the DNA damage response via PARP inhibition with olaparib enhanced E2-induced DNA damage. PARP inhibition synergized with E2 to suppress growth and prevent tumor recurrence in BRCA1/2-mutant and BRCA1/2-wild-type cell line and PDX models. Conclusions: E2-induced ER activity drives DNA damage and growth inhibition in endocrine-resistant breast cancer cells. Inhibition of the DNA damage response using drugs such as PARP inhibitors can enhance therapeutic response to E2. These findings warrant clinical exploration of the combination of E2 with DNA damage response inhibitors in advanced ER+ breast cancer, and suggest that PARP inhibitors may synergize with therapeutics that exacerbate transcriptional stress.

28 June 2023 in Cancer Cytopathology
Verified
Journal Article
Closed access
JLJoshua Levy
Joshua Levy
NCNatt Chan
Natt Chan
JMJonathan D. Marotti
Jonathan D. Marotti
DKDarcy A. Kerr
Darcy A. Kerr
EGEdward J. Gutmann
Edward J. Gutmann
LVLouis J. Vaickus
Louis J. Vaickus